Market Overview
Global Brucellosis Vaccines market size was valued at USD 10.8 million in 2024. The market is projected to grow from USD 11.2 million in 2025 to USD 14.1 million by 2032, exhibiting a CAGR of 4.0% during the forecast period.
Brucellosis vaccines are specialized biological products designed to prevent brucellosis in livestock, primarily cattle, sheep, and goats. These vaccines stimulate an immune response against Brucella bacteria, which cause significant economic losses in animal husbandry due to reproductive failures.
The most commonly used vaccine strains include S19 (live attenuated) and RB51 (rough mutant strain), each offering distinct advantages for different animal populations.
USD 10.8 million in 2024
2032 USD 14.1 million by 2032
of 4.0%
S19 Vaccine Segment Leads the Market Due to Widespread Adoption in Cattle and Sheep Vaccination Programs
The market is segmented based on type into:
S19 Vaccine Key application: Primarily used for cattle and sheep immunization
RB51 Vaccine Strain
Other emerging vaccine types
By Application
Cattle Vaccination Represents the Largest Application Segment Due to High Disease Prevalence in Dairy and Beef Industries The market is segmented based on application into:
Cattle Sheep Goatsa Other livestock
Portable Neuromonitoring Device Market
Our Key Players
Jinyu Group (China)
Colorado Serum Company (U.S.)
Boehringer Ingelheim Animal Health (Germany)
Biogenesis-Bago (Argentina)
Vetal Company (Serbia)
CZ Veterinaria (Spain)
https://www.24lifesciences.com/dow
https://www.24lifesciences.com
